EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited

View source ↗

Summary

Dimethyl fumarate Mylan has been authorised for use in the European Union as a treatment for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate Mylan (dimethyl fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Mylan Pharmaceuticals Limited. Decision date: 21/07/2026